Pharmedica USA’s Phoenix, Ariz., drug manufacturing facility was cited by the FDA in a warning letter for lack of a sterile environment for producing its OTC eye drops and for having a manufacturing facility that “was in a state of disrepair.”
Source: Drug Industry Daily